Go to deals
Healthcare

GeneTech Inc. has been acquired by Eurofins

Noritsu Koki Co., Ltd. has sold GeneTech Inc. to Eurofins Clinical Testing Holding Lux S.à r.l.

GeneTech is a provider of non-invasive prenatal genetic tests (NIPT). The tests can only be taken at facilities certified by the Japanese Association of Medical Sciences. As a result of these efforts, GeneTech has carried out more than 90% of the NIPT tests conducted in Japan. Additionally, based on the achievements and experience accumulated, the firm has delivered various academic information and peripheral services to medical institutions.

Incorporated in 2014, Eurofins Clinical Testing Holding Lux S.à r.l. is a global clinical test service provider based in Luxembourg.

Founded in 1951, Noritsu Koki is a Tokyo Stock First Section listed public conglomerate specializing in manufacturing and healthcare businesses.

Oaklins’ team in Japan acted as the exclusive financial advisor to Noritsu Koki Co., Ltd. in this transaction.

Service
M&A sell-side
Parties

Talk to the deal team

 Taro  Okayama

Taro Okayama

Managing Director

Tokyo, Japan
Oaklins SXA
 Yasuhiro  Yasumuro

Yasuhiro Yasumuro

Director

Tokyo, Japan
Oaklins SXA

Related deals

Gilde Healthcare has invested in Tandarts Today
Private Equity | Healthcare

Gilde Healthcare has invested in Tandarts Today

Gilde Healthcare has invested in Tandarts Today, a fast-growing dental chain in the Netherlands. The investment will allow Tandarts Today to accelerate its buy-and-build strategy and become a leading dental chain in the Netherlands. Financial details have not been disclosed.

Learn more
Alcidion (ASX:ALC) has acquired ExtraMed
Healthcare

Alcidion (ASX:ALC) has acquired ExtraMed

Alcidion (ASX:ALC) has acquired ExtraMed Ltd., a UK provider of patient flow management software that helps address key pain-points for hospital administrative staff.

Learn more
Alcidion (ASX:ALC) has completed a capital raise
Healthcare

Alcidion (ASX:ALC) has completed a capital raise

Alcidion (ASX:ALC) has raised funds to continue its growth strategy.

Learn more